Doug Kerr
InvestorScience Advisor at Exceptional Ventures
Boston/Cambridge
Writes $100K – $5M checks · typically $1.5M
About
Science Advisor and Chief Medical Officer at Generation Bio, a gene therapy company he co-founded. Holds an MD and PhD, was a professor at Johns Hopkins, and led development of the SMA therapy Spinraza.
Experience
- Dyne TherapeuticsChief Medical Officercurrent2024 — presentWaltham, Massachusetts, United States
- Trace NeurosciencesMember, Board and SABcurrent2024 — presentSan Francisco Bay Area
- BlueRock TherapeuticsBoard Membercurrent2023 — presentCambridge, Massachusetts, United States
- GenRab TherapeuticsBoard Membercurrent2022 — presentDallas, Texas, United States
- Exceptional VenturesAdvisor and LPcurrent2022 — presentGreater London, England, United Kingdom
- Siegel Rare Neuroimmune AssociationMember, Board and SABcurrent2009 — presentColumbus, Ohio Metropolitan Area
- Atlas VentureVenture Partner2024 — 2025Cambridge, Massachusetts, United States
- AAVantgarde BioBoard Member2023 — 2025Milan, Lombardy, Italy
- Generation BioChief Medical Officer2020 — 2024Cambridge, Massachusetts, United States
- Generation BioChief Development Officer2019 — 2020Cambridge, Massachusetts, United States
- Generation BioEVP, Head of Preclinical Research & Clinical Development2018 — 2019Cambridge MA
- Generation BioEVP Head of R & D, Chief Scientific Officer2017 — 2018Cambridge MA
- Faze MedicinesBoard Member, Chair Compensation Committee2021 — 2023Cambridge MA
- Triplet TherapeuticsBoard Member2019 — 2023Cambridge, Massachusetts
- Disarm TherapeuticsMember, Scientific Advisory Board2018 — 2020Cambridge, Massachusetts
- CureSMABoard of Directors, Chair Science and Medicine Committee2018 — 2020Illinois
- ShireGlobal VP Neurology Development Lead2015 — 2017Lexington MA
- BiogenSenior Director, Corporate Strategy and Portfolio Management2014 — 2015
- BiogenSenior Medical Director Research and Development, Neurodegeneration2013 — 2015
- BiogenSenior Medical Director2013 — 2014
Education
- Princeton UniversityBA, Biology1984 — 1988
- Northeastern UniversityMaster of Business Administration (MBA), Business Administration and Management2012 — 2014
- The Johns Hopkins University School of MedicineNeurology Residency Program1996 — 1999
- Jefferson HealthMD/PhD, molecular neurovirology1988 — 1995
Skills & more
Molecular Biology8Neurology33Clinical Development6Drug Development27Lifesciences7Neuroscience11Immunology7Clinical Trials34Biochemistry5Spine1Biotechnology21Genetics3
+12 more
Pharmaceutical IndustryCell BiologyBioinformaticsLife SciencesDrug DiscoveryMedicinePharmacologyCancerClinical ResearchStem CellsInfectious DiseasesCell CultureFrom Doug's professional profile.
Colleagues at Exceptional Ventures
Alex Laterza
Advisor at Exceptional Ventures
Alex Söderman
CFO & Compliance Officer at Exceptional Ventures
Anna Fortuny-Gomez
Head of Platform, Science, & Reputation at Exceptional Ventures
Federica Pio
Scout at Exceptional Ventures
Federico Raoul Cucchi
Partner at Exceptional Ventures
Frederica Dick-Read
Executive Assistant at Exceptional Ventures
Jason Foster
Scout at Exceptional Ventures
Joan Miquel Marcos Salleras
Visiting Analyst at Exceptional Ventures
Network4
Alex Laterza
Advisor at Exceptional Ventures
Alex Söderman
CFO & Compliance Officer at Exceptional Ventures
Federico Raoul Cucchi
Partner at Exceptional Ventures
Raj Singh
Investor at Exceptional Ventures
Investors connected to Doug in public investor directories — a warm-intro map.
Frequently asked questions
- Where does Doug Kerr work?
- Doug Kerr is Science Advisor at Exceptional Ventures.
- What check size does Doug Kerr write?
- Doug Kerr typically writes checks of $100K – $5M.
Same school
Also attended Princeton University551
Fabrice GrindaCo-founder & Managing Partner at FJ LabsAndrewAdvisor at Clear VenturesChristal NgAssociate at Golden Gate VenturesDavid CoatsManaging Director & Co-Founder at Correlation VenturesDan MoreheadFounder & CEO at Pantera CapitalHoward CoxSpecial Limited Partner at Greylock Partners
+ 545 more
Also attended Northeastern University259
Matt GuineyChief Financial Officer at Flybridge Capital PartnersSaunaz MoradiPartner, Communications at Lux CapitalBrian DixonManaging Partner at Kapor CapitalMurat BicerGeneral Partner at CRV (Charles River Ventures)Arjun BalajiPartner, Investing & Research at ParadigmAyesha AroraVenture Partner at S32
+ 253 more
Also attended The Johns Hopkins University School of Medicine25
Hal PazInvestor at Khosla VenturesRochelle WalenskyExecutive Partner at Flare Capital PartnersBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersS.K. LeeExecutive Coach at Roble VenturesKayarash KarimianSenior Associate at Cure VenturesSamantha GuinnAnalyst at Novartis Venture Fund
+ 19 more
Shared employers
Also worked at Dyne Therapeutics5
Also worked at BlueRock Therapeutics2
Also worked at Atlas Venture58
Karim FarisInvestor at GV (Google Ventures)Nessan BerminghamInvestor at Khosla VenturesKristen LaguerreExecutive Partner at MPM BioImpactGretchen McCareyChief Financial Officer at Castle Island VenturesKate GunioController at Long Ridge Equity PartnersHenri MoissinacInvestor at FELIX CAPITAL
+ 52 more

















.jpg)

.png)









.png)

















